Counsel registry
Hyperice
2 case appearances — 1 as plaintiff counsel · 1 as defendant counsel.
Firm overview
I'll verify the entity and its litigation footprint before drafting.
The structured record labels "Hyperice" as a firm, but the underlying data points to a corporate in-house IP program. Let me verify that and the outside-counsel picture.
Important framing note: Despite the "Firm profile" label above, Hyperice is not a law firm. It is a privately held consumer medical/wellness device manufacturer — Hyper Ice, Inc. (dba Hyperice), 525 Technology Drive, Suite 100, Irvine, California — founded in 2011 (some sources say 2010), best known for the Hypervolt percussive massage gun. The two "tracked appearances" are in-house counsel entries, not law-firm engagements: Brian G. Arnold is Hyperice's Associate General Counsel and Head of IP (California Bar No. 186007, business address of record at Hyperice in Irvine). What the record actually documents is Hyperice's corporate IP enforcement program, not a firm practice. AmLaw, Chambers, Vault and attorney-count/revenue metrics therefore do not apply, and I have not supplied any.
What the entity does. Hyperice sells percussion (Hypervolt), dynamic air compression (Normatec), vibration (Vyper, Hypersphere), thermal (Venom) and contrast-therapy (Hyperice X) products through consumer, retail, team and clinical channels. Reported valuation was roughly $850M in 2024 (Orange County Business Journal); CB Insights reports total funding of about $148M. It holds a substantial worldwide patent portfolio; CB Insights counts roughly 110 patent filings. In-house IP leadership is Brian G. Arnold, who came to the company after roles as a patent litigation partner at Kirkland & Ellis and most recently Lewis Roca Rothgerber Christie. Hyperice's General Counsel is Jon Howell; CEO is Jim Huether. Hyperice also maintains a dedicated IP holding subsidiary, Hyperice IP Subco, LLC, which owns the asserted patents and is the named patent owner/respondent in the PTAB proceedings.
Litigation posture — predominantly plaintiff-side enforcement, with a defensive flank. Per the structured counts Hyperice appears once as plaintiff and once as defendant; the fuller public docket shows the plaintiff side is dominant. Beginning with the January 2024 assertion of U.S. Patent No. 11,857,482 against rival Therabody, Hyperice ran a coordinated, category-wide campaign in C.D. Cal., E.D. Mich. and W.D. Tex. against competitors and downstream retailers — Therabody, MerchSource, FKA Distributing, Joicom, Dacorm, Toloco, "Bob and Brad," Costco, Macy's, Kohl's, TJX, Lowe's, Target, CVS and Walgreens, among others. The defendant-side entry corresponds to Therabody's counter-campaign: Therabody, Inc. v. Hyper Ice, Inc., No. 8:26-cv-00003 (C.D. Cal., filed Jan. 2, 2026, asserting U.S. Patent No. 12,396,919), plus Therabody's post-grant challenges. This is operating-company-versus-operating-company litigation, not NPE/PAE assertion.
Notable matters and public outcomes. The lead infringement actions (8:24-cv-00390, later consolidated into 8:24-cv-02034; and 8:25-cv-01939, consolidated into the earlier case in November 2025) remain pending before Judge John W. Holcomb, with claim construction activity in 2026. The W.D. Tex. Costco action was stayed and administratively closed by joint motion in May 2024, tied to the California and Michigan cases. On the enforcement side, Hyperice's earlier ITC Investigation No. 337-TA-1206 produced findings of infringement of the '574 patent by defaulting Chinese massage-gun respondents and an exclusion order — a real, verifiable win, though I could not independently reconfirm the Commission's final determination text within this run. A Lewis Roca press release (now hosted on Womble Bond Dickinson's site following the 2025 combination) also describes a PTAB win for Hyperice against Sharper Image, achieved by statutorily disclaiming six unasserted claims to prevent institution. Treat the firm attribution in that release as historical — Arnold is now in-house.
PTAB / PGR activity. This is the most active and best-documented part of the dispute, and Hyperice is on both sides. As patent owner, Hyperice IP Subco defended PGR2024-00053 (Therabody challenging the '482 patent), which was instituted April 21, 2025 and reached a final written decision on April 20, 2026, now on appeal at the Federal Circuit (No. 26-1949, filed June 17, 2026); and PGR2025-00013 (challenging the '082 patent), instituted July 2, 2025, decided May 11, 2026 with the claims upheld as patentable, and also appealed (No. 26-1950). As petitioner, Hyperice filed PGR2026-00051 against Therabody on May 26, 2026, which remains pending. Hyperice's IPR/PGR volume is therefore best characterized as a handful of high-stakes, case-linked proceedings tied to its district court campaign, not a docket-scale PTAB practice.
Outside counsel (for context, since the requested partner list has no law-firm counterpart). Hyperice is represented in the California campaign by Miller Barondess LLP (Ben Herbert) and Lewis Brisbois Bisgaard & Smith LLP (Lawrence LaPorte), with Arnold as in-house counsel of record. Lewis Roca (Kyle Kellar, Kurt Prange) handled prior PTAB and district court matters. Therabody is represented by Renner Otto and Byron Raphael LLP, among others. One caveat worth stating plainly: public reporting on the which-firm-for-which-matter allocation is inconsistent across sources and dates, so any partner-level attribution should be re-verified against current dockets before being relied on.
Attorneys
Roles
- in-house2
Cases (2)
- π plaintiffHyper Ice, Inc. et al. v. Therabody, Inc.Brian G. Arnold · in-house
- Δ defendantTherabody Inc. v. Hyperice IP Subco LLCBrian G. Arnold · in-house